ewsba.se
Aarti Drugs shares rallied over 10.88% in Monday's trading session defying weak sentiments in the Indian stock market. The pharma stock opened at ₹457 apiece on the BSE and surged to an intraday high of ₹513, registering strong buying interest during the session.
Meanwhile, the broader market remained under pressure. The Sensex and Nifty traded lower as investors booked profits following a sharp seven-session rally through Friday, during which benchmark indices gained around 10.5%. The Sensex was down around 0.2% in early trade, while the Nifty 50 slipped below the 25,000 mark. Against this backdrop, Aarti Drugs shares emerged as a notable outperformer.
The stock rally came in after Aarti Drugs shares witnessed a spurt in its trading volume. According to data available on NSE, around 348.19 lakh shares changed hands during the intraday session on Monday.
Aarti Drugs reported a strong set of financial results for the September quarter of FY27, with consolidated net profit rising 83% YoY to ₹82.8 crore, compared with ₹45.2 crore in the corresponding quarter last year.
The company's consolidated revenue increased 27% YoY to ₹828.8 crore from ₹652.9 crore in Q2 FY26. Earnings before interest, taxes, depreciation and amortisation (EBITDA) jumped 63% to ₹137.9 crore against ₹84.4 crore in the year-ago quarter.
Operating performance also improved, with EBITDA margin expanding 370 basis points to 16.6% from 12.9% a year earlier. Profit after tax (PAT) margin increased 310 basis points to 10% from 6.9%.
Segment-wise, revenue from the active pharmaceutical ingredients (API) business grew 17% YoY to ₹604.5 crore. Formulation revenue surged 58% to ₹130 crore, while specialty chemicals revenue nearly doubled, increasing 92% to ₹71.8 crore.
For the first half of FY27, consolidated revenue increased 23% YoY to ₹1,532.4 crore, while EBITDA rose 48% to ₹234.8 crore. Net profit grew 34% to ₹132.9 crore.
The company attributed its performance to volume growth, stronger realisations across its API, formulations and specialty chemicals businesses, and progress in building an integrated manufacturing platform.
Apart from its strong quarterly earnings, in an exchange filing dated November 6, the company informed that the US Food and Drug Administration (US FDA) inspected wholly owned subsidiary Pinnacle Life Science's formulations manufacturing facility in Baddi, Himachal Pradesh, between November 2 and November 6, 2026.
Following the inspection, the subsidiary received three inspectional observations in Form 483. The company clarified that none of the observations were related to data integrity and said it would work closely with the US FDA to resolve all the points.
Importantly, Aarti Drugs stated that the observations would have no impact on the financial or operational activities of the company or its subsidiary.
The regulatory update is an important development for investors tracking the company's manufacturing operations and regulatory compliance, particularly as it looks to expand its presence in regulated markets.
Aarti Drugs shares have witnessed renewed buying interest in recent sessions, supported by the company's strong Q2 FY27 earnings and improving operating performance.
According to available market data, the stock has gained around 12.24% over the past week and 23.30% over the past month. It has delivered a year-to-date return of 23.67%, while its one-year return remains negative at 1.95%.
Over longer periods, the stock has gained 4.98% in three years but declined 9.39% over five years.
Disclaimer: This story is for educational purposes only. Please consult with an investment advisor before making any investment decisions.
Vaamanaa covers business and stock market news. Started in 2020, she has been producing news on digital platforms for over 4.5 years now. She writes on markets, commodities, IPOs, and industry. She has worked for news channels like Jagran New Media and Business Insider India. You can reach out to her at vaamanaa.sethi@htdigital.in.
Catch all the Business News , Market News , Breaking News Events, JIO IPO Listing Today LIVE and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.